Hill-Rom launches Envella therapy bed for wound care patients



Hill-Rom Holdings (NYSE:HRC) said today it launched its Envella air fluidized therapy bed designed for wound care and patients with advanced wounds.

The Envella bed was unveiled at the Wound Ostomy and Continence Nurses Society Annual Conference in Salt Lake City, Utah this week, the Chicago-based company said.

Hill-Rom said that the Envella air fluidized therapy bed is designed to maximize immersion and envelopment and minimize shear and pressure, as well as regulating the skin’s microclimate. The company claims the technology can lead to better outcomes in patients with complex and advanced wounds .

“Pressure injuries present a significant challenge for the entire healthcare environment. Across the care continuum, pressure injuries are quite common, cause serious concerns both to patients and their caregivers, and create financial burdens for the healthcare system. The Envella bed’s differentiated technology provides an ideal healing environment for the prevention and treatment of advanced pressure injuries,” patient support systems prez Paul Johnson said in a press release.

In April, Hill-Rom said it launched the Monarch airway clearance system designed to provide high frequency chest wall oscillation.

The Monarch device is a mobile vest which uses personal oscillating discs to provide targeted kinetic energy and HFCWO to the lungs to thin mucus and generate airflow, the company said.

Smith & Nephew gains as emerging markets boost Q1 results

Smith & NephewSmith & Nephew (NYSE:SNN) shares are up today in London and New York after the British medical device giant said emerging markets drove strong 1st-quarter results.

Overall sales grew 0.4% to $1.14 billion and 3% on a constant-currency basis for the 3 months ended April 1, the company said. Smith & Nephew no longer reports quarterly profits or earnings. Although sales fell in both the U.S. and established markets overseas, emerging market revenues jumped 13.1% to $173 million compared with Q1 2016.

“I am pleased with the start of 2017, which was in-line with our expectations. In particular, performance in the emerging markets was good, returning to double-digit growth, with China up 14% underlying. Our innovative new products, such as the Lens camera and Werewolf Coblation systems, have been well received, and we look forward to the imminent full market release of the total knee application on our Navio robotics-assisted surgery system,” CEO Olivier Bohuon said in prepared remarks. “Over the last few years we have successfully put in place the right structures and capabilities to make the group stronger, simpler, more agile and efficient. We continue to focus on execution and expect to see progress through the year.”

Smith & Nephew said it still expects to add 20 to 70 basis points to its trading profit this year, on constant-currency sales growth of 3% to 4%.

During a conference call with analysts, Bohuon said he’s focused on organic growth in the short term, rather than acquisitions. Analyst chatter earlier this year had Smith & Nephew as the most likely acquirer of extremity orthopedics maker Wright Medical (NSDQ:WMGI).

Although M&A is “always on the agenda” and acknowledging that extremities are an area of interest for Smith & Nephew, “for the moment, this quarter, I am interested in developing my commercial excellence,” Bohuon said.

“[M&A] is still high on the agenda, but it’s not a top priority for the time being,” he said.

SN shares were up 2.5% to £13.02 apiece today as of about 11:30 a.m. in London; SNN shares rose 3.0% to $33.11 each in pre-market trading in New York.

Material from Reuters was used in this report.

Origin treats first patients in study of nitric oxide for diabetic foot ulcers

Origin treats first patients in study of nitric oxide for diabetic foot ulcersOrigin said today that it treated the 1st patients in its dose-ranging Genesis Phase IIb-equivalent trial. The study is evaluating therapeutic quantities of plasma-generated nitric oxide as a treatment for chronic diabetic foot ulcers.

The 27-week trial is slated to enroll up to 100 patients. Patients will be randomized into 1 of 4 dosing regimens, or receive standard of care as a control, to assess the safety and efficacy of plasma-generated nitric oxide, according to Origin. The company plans to treat the participants for 12 weeks and monitor them for 12 weeks following treatment.

Get the full story at our sister site, Drug Delivery Business News.